A due diligence conversation about clinical data used to end once a team could show the study cleared its regulatory bar. That is no longer where the conversation ends. Investors increasingly treat regulatory clearance as the floor, not the finish line, and the real question they are asking is different: does this evidence let the company win once the device is on the market.
That shift changes what good clinical evidence looks like from an investor's chair. A study built strictly to hit a primary endpoint for FDA clearance or a CE mark can succeed completely and still say nothing about why a clinician should choose this device over the one already on the shelf, why a payer should reimburse it, or what a sales team can point to when a hospital asks for proof.
Regulatory clearance answers one question: is the device safe and effective enough to be sold. It does not answer the question an investor actually cares about, which is whether the company can turn that clearance into adoption, pricing power, and a defensible position once competitors respond. Market access is not the same as market adoption: a device can be fully cleared and still lose to an entrenched predicate if there is no evidence showing it is meaningfully better.
Investors who have sat through more than one of these conversations know the pattern well. A founder presents a clean, well-run study that cleared its bar on schedule. The investor's next question is rarely about the p-value. It is about what else the data can support: a comparator claim, a subgroup finding, a health economic argument, anything that gives the sales team, the payer conversation, or the next funding round something more to work with than "it works."
Clinical evidence increasingly decides adoption in a value-based healthcare system, where two similar devices at similar price points compete on the strength of the data behind them, not the device alone. That is the commercial case investors are underwriting when they fund a clinical program: not just a path through the FDA or a notified body, but a path to the claims that win a hospital contract, support a premium price, or make a payer say yes.
The deeper breakdown of what separates evidence that clears a bar from evidence that moves a market, statistical significance, clinical significance, and commercial significance, is covered in the clinical evidence investors actually care about. The short version: a result can be statistically airtight and still be commercially irrelevant if it does not answer a question a buyer actually has.
Not every investor asks about study design or endpoints on a first call. Plenty of first conversations stay at the level of the pitch: what the device does, what the market looks like, what the clinical program has shown so far. The differentiation question usually surfaces later, once diligence gets underway and someone on the investment team, or a technical advisor brought in for the process, starts asking what the data actually supports beyond clearance.
None of the commercial claims above survive being pressure-tested if the study that generated them cannot be defended. Three setups show up again and again in early clinical programs, and each one quietly puts the differentiation story at risk.
Running the study in a spreadsheet is the most common. It has no audit trail, no field-level validation, and nothing that shows a regulator, or a diligence team, that a value was entered correctly the first time and never changed without a record. Electronic data capture vs. paper for clinical data lays out exactly what that gap costs once a study is underway. Kerecis ran its early studies in Excel and found the approach time-consuming and not aligned with EU MDR requirements. After moving to a purpose-built platform, the team reached full data compliance in both the United States and Europe and cut manual data entry out of the process entirely.
The second is running the study inside a CRO's own platform, one of the most common paths for a first study and, in most cases, a perfectly practical one. CROs bring execution expertise a lean manufacturer does not have in house, and their track record with regulatory pathways and notified bodies is often worth paying for even when it costs more upfront than relying on a site's own investigators. The detail worth surfacing in diligence is narrower: which platform holds the data, and how easily the manufacturer can access, export, and reuse it on its own. Investors who have sat through enough of these conversations also check a related thing: whether the endpoints and sample size were locked in before the study ran rather than chosen afterward to match whatever result came out, and whether the operational standard, ISO 14155, FDA's recordkeeping requirements under Part 11, good clinical practice, was followed on paper as consistently as it was in the room. Under ISO 14155 and EU MDR, responsibility for the clinical evidence sits with the manufacturer regardless of who ran the study, so that access question matters on its own terms. It is not a judgment on the CRO.
The third is a generic or pharma-heritage electronic data capture (EDC) platform configured to approximate a device study. What you give up when your device study runs on a pharma EDC covers this in detail: the configuration effort, the validation burden, and the data that still carries the platform's original assumptions once the study is running.
None of these three defaults are reckless decisions. They are what a lean team reaches for under time pressure. But a differentiation claim built on top of any of them is a claim that has not been stress-tested yet, and diligence is where that test happens.
The instinct to fix this by avoiding CROs entirely is the wrong lesson. A manufacturer can work with a CRO for execution and still own the platform the data sits in, which keeps access, export, and long-term reuse in the manufacturer's hands regardless of who runs the day-to-day study. In practice, that kind of ownership does not require a clinical operations department on day one. The setup that tends to work for a lean team is a hybrid one: one part-time person inside the company who owns the data and the strategy, paired with an outsourced regulatory or CRO partner who handles execution. That in-house person does not need to run the study day to day. They need to be the one who can pull the data, answer for it, and know where every piece of it lives, so ownership does not quietly become whatever the outsourced partner's system defaults to. As the program matures toward submission, that part-time role usually grows into a full-time clinical affairs hire.
Getting this right early matters more the longer a company's clinical program runs. Feasibility data collected under a first-in-human study is exactly what a submission needs two years later, and exactly what a notified body wants during post-market clinical follow-up. If that evidence sits inside a system the manufacturer cannot freely access, the team is rebuilding history under deadline pressure instead of pulling a report, exactly the scenario FDA's guidance on electronic records and signatures in clinical investigations is meant to help teams avoid. Clinical evidence for first-time study teams walks through the specific decisions, on data ownership, audit trails, and CRO oversight, that determine which position a company is in when that moment arrives. The companion piece on why your QMS is an investor credibility signal covers the parallel case for design history and document control.
None of this requires an enterprise clinical operations department, and that is the part worth saying plainly to a founder weighing the cost of getting it right early. Loop Medical, a Class II device company running studies across multiple countries, moved off a paper-based process that offered little visibility and slowed everything down. Using a platform built for device studies, the team set up a new international study in a couple of weeks without anyone working on it full time, and real-time access to the data saved both time and money. As Alison Moran, the company's clinical affairs manager, put it, the platform "made data collection faster and easier and removed headaches."
That is a small team owning its evidence without adding headcount, and it is what sound clinical data management looks like without an enterprise build. It also frees up a team's attention for the part of the study that actually determines commercial outcome: the endpoints, comparators, and subgroup questions that give the evidence something to say beyond clearance. Running the study on Greenlight Guru Clinical, a platform purpose-built for medtech clinical data capture, is what made that possible, since ownership and access came built in instead of bolted on. The real-world data generated in studies like this also compounds over time. Real-world data and evidence for devices covers how early clinical data continues to earn its value well past the first submission, exactly the kind of long-run differentiation asset a diligence team wants to see building.
Everything above is written for the founder across the table. The same two-part test, does the evidence differentiate the product, and can the underlying system be trusted, is worth applying from your side too, and it gets harder to apply well across a full portfolio.
A single company's clinical program is manageable to evaluate once. A dozen portfolio companies, each with a different study platform, a different data ownership arrangement, and a different answer to what the data actually proves, is not something you can track from memory. The commercial-differentiation question changes company to company. The backbone question, can this team produce, defend, and reuse this data on demand, stays consistent, and it is worth asking as a standard part of every clinical diligence conversation rather than reserving it for the companies that raise a flag.
The exit case is where both questions compound. A buyer's technical diligence team will ask the same two things: what does this evidence prove that a competitor's does not, and can you produce the full file on demand in a usable format. A portfolio company that has a clear differentiation answer and owns its evidence answers both in an afternoon. One that has neither starts a longer, more expensive conversation right when speed matters most.
What is the difference between clinical evidence that clears regulatory approval and evidence that helps a company raise or exit? Regulatory clearance shows a device is safe and effective enough to sell. Investors also want evidence that supports commercial claims, comparator data, subgroup findings, health economic arguments, that help the device win adoption, pricing, and market share once it is cleared.
What do investors look for in clinical evidence during due diligence? Increasingly, whether the evidence differentiates the product commercially, not just whether the study succeeded, and whether the manufacturer controls the system the data lives in well enough to defend and reuse it on demand.
Who owns clinical trial data when a CRO runs the study? Under ISO 14155 and EU MDR, the manufacturer holds regulatory responsibility for the clinical evidence regardless of who executes the study. Practical data ownership, meaning access, export, and reuse, depends on which platform the study runs on, not on who staffs it.
Why does clinical data ownership matter for a medtech exit? A buyer's technical diligence team wants to know what the evidence proves competitively and whether the manufacturer can produce the full file on demand. A manufacturer with both answers ready moves through diligence in a fraction of the time.
If you are thinking through fundraising and clinical evidence readiness at the same time, these go deeper on the specific pieces:
Whether you are the founder building this evidence or the investor asking about it, the fastest way to see what a diligence-ready, differentiation-ready clinical program looks like is to see it running. Get a demo of Greenlight Guru Clinical and walk through it before you need to explain it under pressure.